Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy
Keywords: Resistant associated variants (RAVs); Hepatitis C virus (HCV); Direct acting antiviral (DAA); Sofosbuvir (SOF); NS5B inhibitor;